NAT MED: China's largest new crown antibody epidemic release

Detection of asymptomatic or subclinical new human coronavirus SARS-CoV-2infectionis critical to understanding the overall prevalenceandpotential ofCOVID-19Recently, in order to estimate the cumulative prevalence of SARS-CoV-2 infection in China, by measuring the levels ofimmuno
globulinM M and G, Chinese researchers assessed host serum reactions in Wuhan, China, and various geographic regions of the country between March 9, 2020 and April 10, 2020in the queue, the seropositive rate of different subgroups in Wuhan was between 3.2% and 3.8%With the increase of distance from Wuhan, the seropositive in other cities gradually decreasedPatients and health care providers who went to the hospital for maintenance hemodialysis also had a higher serum prevalence rate of 3.3% (51 out of 1,542, 5.5-4.3%, 95% Confidence Zone (CI) and 1.8% (81 out of 4,384, 1.5-2.3%, 95% CI)we need more research to determine whether these results can be extended to other populations and geographic locations, and to determine how rapidly serum prevalence increases as the COVID-19 pandemic progressesserological monitoring has the potential to provide a more faithful cumulative viral attack rate for the first season of this new type of SARS-CoV-2 infection